Action and function of Chromobacterium violaceum in health and disease: Violacein as a promising metabolite to counteract gastroenterological diseases

Autor(es)

Justo, Giselle Zenker ^{[1, 2]} ; Duran, Nelson ^{[3, 4, 5]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo UNIFESP, Dept Pharmaceut Sci, 3 Maio, 100, BR-04044020 Sao Paulo, SP - Brazil

^[2] Univ Fed Sao Paulo UNIFESP, Dept Biochem, 3 Maio, 100, BR-04044020 Sao Paulo, SP - Brazil

^[3] Univ Estadual Campinas, Inst Chem, NanoBioss, Campinas, SP - Brazil

^[4] Univ Estadual Campinas, Inst Chem, Biol Chem Lab, CP 6154, BR-13083970 Campinas, SP - Brazil

^[5] LNNano CNPEM, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY; v. 31, n. 6, p. 649-656, DEC 2017.
• Citações Web of Science: 2

Resumo

Chromobacterium violaceum is a Gram negative, beta-proteobacterium found in the microbiota of tropical and subtropical environments. Although considered an opportunistic pathogen, infection rapidly progress to fatal sepsis, with metastatic abscesses. It is noteworthy the multidrug resistant phenotype of C. violaceum and the possibility of relapse. Recently, an influence of global climate in the incidence of cases beyond the previous areas has been observed, Furthermore, chronic granulomatous disease has been considered a risk factor to infection. Despite the increase in C. violaceum infection incidence and high mortality, most clinicians are not familiar with it. This review pointed out important features of this life threatening microorganism, including its pathogenicity, mechanistic aspects, genetic and drug resistance associated factors, and the clinical association with chronic granulomatous disease. In addition, its main metabolite violacein may be a promising agent to counteract gastroenterological diseases, such as colorectal cancer and inflammatory gastric lesions. (C) 2017 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 08/51116-0 - Potencial antileucêmico e mecanismos de ação de compostos bioativos em células primárias de leucemia mielóide aguda
• Beneficiário: Giselle Zenker Justo
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores